Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
- 28 February 2007
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 16 (1) , 86-93
- https://doi.org/10.1016/j.breast.2006.06.008
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Gene Expression Profiles of Breast Cancer Obtained from Core Cut Biopsies Before Neoadjuvant Docetaxel, Adriamycin, and Cyclophoshamide Chemotherapy Correlate with Routine Prognostic Markers and Could Be Used to Identify Predictive SignaturesZentralblatt Fur Gynakologie, 2006
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2005
- In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot studyAnnals of Oncology, 2005
- HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 2004
- Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based ChemotherapyOncology, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Identification of high risk breast-cancer patients by gene expression profilingThe Lancet, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001